BT Pharma, a Labège, France-based biopharmaceutical company developing innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), has raised €13.1m in additional funding and changed its name to Genticel.
The round was led by AGF Private Equity, with participation from three new investors, IRDI (Institut Régional de Développement Industriel), Amundi Private Equity Funds and InnoBio fund, managed by CDC Entreprises, within FSI France Investment program.
Previous investors, including Edmond de Rothschild Investment Partners (EdRIP), also took part.
The new funding will enable the company to conduct:
– “first-in-man” clinical trial with its therapeutic vaccine platform, Adenylate Cyclase (CyaA) focusing its efforts on the prevention of cervical cancer in HPV infected women;
– a phase I clinical trial of Genticel’s lead therapeutic HPV vaccine, ProCervix, which should offer a curative vaccine solution that will complement current prophylactic vaccines.
In conjunction with the funding, Dr Alain Munoz, MD, representative of AGF Private Equity, has joined the supervisory board of the company.